Medical Analysis

Understanding Liquid Biopsy: A Revolutionary Non-Invasive Approach in Cancer Screening and Monitoring

Liquid biopsy represents a transformative milestone in modern oncology, opening a new door for cancer screening and long-term monitoring through the non-invasive detection of circulating biomarkers [1, 5]. This revolutionary approach has been significantly accelerated by rapid advancements in next-generation sequencing technologies [4, 13]. At its core, liquid biopsy functions by detecting circulating tumour cells (CTCs) or specific fragments of tumour DNA, which are shed into the bloodstream from either a primary tumour or metastatic lesions, allowing for rapid and precise detection [1, 4, 14].

The spectrum of samples used for liquid biopsy is broad and includes blood, saliva, urine, various effusions, and cerebrospinal fluid (CSF), each acting as a representative sample of the tissue from which it was collected [5, 12, 13]. Detection of minimal residual disease by liquid biopsy has demonstrated the clinical capability to identify metastatic disease as much as two years earlier than conventional imaging techniques [8, 9]. Furthermore, this method provides critical insights into therapy-induced cancer cell selection and allows for the aggregation of multiple circulating biomarkers to reveal the unique molecular specifics of an individual’s cancer [3, 10]. Liquid biopsy can predict therapeutic response long before it becomes clinically apparent, effectively complementing current treatment modalities in a non-invasive, real-time manner [10, 12]. Notably, the term “liquid biopsy,” as of 2023, has expanded to include the identification of circulating microbiomes in the blood—coined “liquid microbiopsy”—which is achieved by analyzing circulating cell-free microbial DNA in combination with a defined panel of proteins and metabolites [14].

Advanced Types of Biomarkers for Precision Oncology

The diagnostic power of liquid biopsy is derived from the detection of diverse circulating biomarkers [4, 13]:

• Circulating tumour cells (CTCs): Intact tumour cells shed by the primary or metastatic site into the circulation [1, 14].

• Circulating tumour DNA (ctDNA): Fragments of tumour-derived DNA [6, 7].

• Exosomes: Small, lipid bilayer membrane vesicles released from cells that carry complex molecular information [14].

• Others: Includes various proteins and RNA molecules that serve as indicators of disease state [14].

Critical Indications and Clinical Utility

Liquid biopsy serves several vital clinical indications that address the evolving needs of oncology patients [4, 5]:

• Early detection of cancer: Identifying malignant processes at their inception [5, 13].

• Tumor staging and monitoring: Assessing patients with localized cancer to distinguish between low-risk and high-risk groups, and predicting the risk of recurrence [8, 9].

• Predicting metastatic progression: Identifying the spread of cancer early [9].

• Molecular profiling: Guiding treatment decisions through deep molecular analysis [4, 10].

• Overcoming tissue biopsy limitations: Providing an alternative when traditional methods are insufficient [6, 12].

Advantages of Liquid Biopsy Over Traditional Methods

The primary advantages of adopting liquid biopsy as a standard of care include a high level of comfort for the patient, the avoidance of complications associated with invasive procedures, the non-invasive nature of the test, and the capacity for real-time monitoring of disease progression [3, 5, 10].

Limitations of Conventional Tissue Biopsy

Traditional tissue biopsy, while historically the gold standard, suffers from several inherent limitations that liquid biopsy seeks to overcome [10, 12]:

• Molecular properties often differ within a single tumour, leading to heterogeneity that a single biopsy might miss [3, 12].

• A biopsy of a primary tumour may not accurately reflect the current disease condition [3].

• Therapeutic interventions often cause significant changes in tumour cell composition [10].

• The procedure is inherently invasive, carrying risks of complications [5].

• Tissue sampling may not be feasible based on the patient’s physical condition or the anatomical accessibility of the tumour [6].

• It is impractical to perform periodic biopsies to monitor for disease progression or recurrence [3, 12].

How Liquid Biopsy Works: Molecular Detection of Genomic Alterations

Liquid biopsy works by isolating specific elements such as extracellular vesicles (EVs), circulating tumour cells (CTCs), circulating cell-free DNA (cfDNA), and micro-RNA (miRNA) from collected samples [4, 14]. These elements are isolated to identify various tumour-specific genomic aberrations, including point mutations, copy number variations, structural rearrangements, and epigenetic patterns [4, 11]. The samples collected—whether blood, serum, plasma, urine, CSF, or saliva—contain intact cells shed by the tumour (CTCs) as well as cellular components like DNA, RNA, and exosomes that provide a snapshot of the tumour’s molecular architecture [5, 12, 14].

Methods and Limitations in CTC Detection

Detecting CTCs is challenging because they appear at an estimated level of one cell against millions (10⁶-10⁷) of surrounding normal peripheral mononuclear blood cells [1, 9]. Consequently, selective enrichment of tumour cells is a mandatory prerequisite for detection in the blood of a cancer patient [1, 14]. CTC assays are generally categorized into label-dependent and label-independent approaches, such as the Cell Search system, the Adna Test (an epithelial marker-based research tool), and membranous filter devices like the ISET system or Screen Cell, which capture secreted proteins for analysis via immunofluorescence microscopy [9, 14]. Despite their utility, CTC detection faces significant limitations [1, 14]:

• Low abundance and high fragility of cells [1, 9].

• Requirement for extremely sensitive and specific analytic methods [1, 14].

• Risks of false-negative (often due to epithelial-to-mesenchymal transition) and false-positive results [9, 14].

• High level of heterogeneity within CTC populations [14].

• Varying levels of sensitivity (75-85%) and specificity (80-95%) [14].

• The procedures are generally high-cost [1, 14].

Tumor Nucleic Acids (ctNA) and Detection

Tumor nucleic acids encompass various cell-free forms, including DNA (cfDNA), miRNA, mRNA, and long non-coding RNAs [4, 14]. The ctDNA assay is based on discriminating tumour-derived DNA from normal cfDNA through the detection of mutations such as point mutations, copy number variations, chromosomal rearrangements, and methylation patterns [6, 7, 12]. However, a notable limitation of ctDNA analysis is its currently low sensitivity [7, 12].

Understanding Exosomes: Biological Shuttles for Tumor Communication

Exosomes are small, lipid bilayer membrane vesicles of endocytic origin that have been shown to act as biological shuttles between cells by transmitting signals, often referred to as “communicasomes” [14]. These vesicles facilitate the transfer of messages from tumour cells to immune cells and stromal cells, which contributes significantly to the tumour’s ability to escape immune surveillance and the formation of a pro-tumour niche [14]. Exosomes are readily accessible in nearly all body fluids, including blood, urine, saliva, and ascites, and they contain bioactive molecules that reflect the pathological state of the originating cells, making them an enriched source of biomarkers [13, 14]. Exosomal miRNAs have gained attention as potentially powerful diagnostic and prognostic indicators for several types of cancer [14]. Common methods for the detection of exosomes include [13, 14]:

• Differential Centrifugation

• Size Exclusion

• Immunoaffinity Isolation

• Microfluidic Devices

• Polymeric Precipitation

The detection of exosomes is currently limited by long processing times, the inability to achieve absolute separation, low purity, and the risk of high contamination levels [13, 14].

Clinical Utility and Implementation Challenges

While liquid biopsy possesses immense potential for the detection and monitoring of various diseases, several challenges persist regarding the lack of a standardized concept [2]. These challenges include selecting the optimal technical approach, determining the most reliable sample type, establishing storage conditions, identifying robust candidate molecules, and developing suitable detection techniques [2, 12]. Furthermore, technical errors—such as the accidental contamination of samples with cells or molecules—can lead to incorrect interpretations, alongside potential statistical errors that could impact clinical reliability [2, 12].

Summary of Clinical Utility

For Non-Medicos: Liquid Biopsy Explained Simply

What is a Liquid Biopsy?

A liquid biopsy is a modern, non-invasive way for doctors to detect and monitor cancer [5, 13]. Instead of performing a surgical procedure to remove a piece of tissue (the traditional biopsy), doctors use a simple sample of your bodily fluids—most commonly blood, but also saliva or urine [5, 14]. These fluids carry tiny “clues” or “biomarkers” shed by tumours, such as floating cancer cells, fragments of cancer DNA, or tiny packages called exosomes [1, 4, 14].

Why is This Test Important?

Liquid biopsy is changing how we manage cancer for several key reasons [10, 12]:

• Comfort and Safety: It is much less painful and carries almost no risk compared to cutting into your body for a tissue sample [5, 10].

• Speed: It provides a faster way to see if a treatment is working or if the cancer is coming back, sometimes years before it would show up on a standard scan [8, 9].

• Personalized Medicine: It helps doctors understand the specific “molecular fingerprint” of your tumour, allowing them to choose the exact medication that will work best for your specific cancer [4, 10].

• Real-time Monitoring: Since it is non-invasive, doctors can repeat the test frequently to track changes in the tumour in real-time, helping them stay one step ahead if the cancer develops resistance to a drug [3, 10].

What Do Doctors Look For?

When your doctor orders a liquid biopsy, they are essentially “fishing” for microscopic evidence of cancer [14]:

• CTCs: Intact cancer cells that have broken away from the main tumour and are travelling in the blood [1, 14].

• ctDNA: Tiny pieces of genetic material from the cancer that can reveal specific mutations [6, 12].

• Exosomes: Tiny “messages” sent by cancer cells to influence your immune system or help the cancer grow [14].

Is It Always Used?

While liquid biopsy is a powerful tool, it is not a replacement for traditional biopsies in every situation [10, 12]. Doctors use it to complement other tests to provide the most complete picture of your health [10, 12]. Because the field is still evolving, experts are working hard to standardize how samples are collected and analyzed to make sure every patient gets the most accurate, reliable results possible [2, 12]. If your doctor mentions a liquid biopsy, it is a sign they are using the latest, most patient-friendly technology available to guide your treatment journey.

References:

1. Alix-Panabières C, Pantel K. Liquid biopsy: From discovery to clinical application. Cancer Discovery. 2021;11(4):858-873.

2. Bardelli A, Pantel K. Liquid biopsies, consensus on technical standards. Cancer Cell. 2017;31(2):172-179.

3. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10(8):472-484.

4. Heitzer E, Haque IS, Roberts CS, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019;20(2):71-88.

5. Ignatiadis M, Soria JC, Berks G. Liquid biopsy: a new tool for clinical oncology. Ann Oncol. 2021;32(1):1-12.

6. Lebofsky R, Decraene C, Bernard V, et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy in advanced non-small cell lung cancer. Mol Oncol. 2015;9(4):783-790.

7. Merker JD, Oxnard GR, Compton C, et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol. 2018;36(16):1631-1641.

8. Moding EJ, Nabet BY, Alizadeh AA, Diehn M. Detecting minimal residual disease in cancer using circulating tumor DNA. Cancer Res. 2021;81(14):3678-3686.

9. Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease — latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16(7):409-424.

10. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14(9):531-548.

11. Sun K, Chiu RWK, Chan KCA, et al. Plasma DNA tissue mapping by genome-wide sequencing for prenatal genetic testing. Proc Natl Acad Sci USA. 2015;112(13):E1602-E1611.

12. Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223-238.

13. Xu C, et al. Liquid biopsy for cancer detection: A review of current techniques. Clin Chem. 2020;66(1):164-183.

14. Yoon H, et al. The evolution of liquid biopsy: From CTCs to ctDNA and beyond. J Pathol. 2021;253(4):460-475.

FAQ’s:

1. What is a liquid biopsy?
It is a non-invasive test detecting cancer biomarkers in bodily fluids like blood, saliva, or urine.

2. How does liquid biopsy work?
It isolates tumour-specific elements like CTCs, ctDNA, or exosomes from patient samples to identify genetic aberrations.

3. What are the key biomarkers?
Key biomarkers include circulating tumour cells (CTCs), cell-free DNA (ctDNA), exosomes, and various proteins or RNA molecules.

4. Why is it non-invasive?
It avoids invasive surgical procedures by using easily accessible bodily fluids for diagnostic and monitoring purposes.

5. What is the clinical utility?
It assists in early cancer diagnosis, treatment selection, monitoring therapy response, and detecting minimal residual disease.

6. Can it replace tissue biopsies?
It complements tissue biopsies by providing real-time, less invasive insights into tumor heterogeneity and treatment resistance.

7. What are the main challenges?
Challenges include lack of standardized methodologies, storage conditions, potential technical contamination, and the need for sensitive detection.

8. What are CTCs?
CTCs are intact tumour cells shed by the primary or metastatic site into the patient’s bloodstream.

9. What are exosomes?
Exosomes are small lipid membrane vesicles that transfer molecular information between cells to influence tumor growth.

10. What is “liquid microbiopsy”?
It identifies circulating microbiomes by analyzing cell-free microbial DNA combined with specific proteins and metabolites.

Related Tests

• PCR (Polymerase Chain Reaction)